Name: | Description: | Size: | Format: | |
---|---|---|---|---|
936.04 KB | Adobe PDF |
Advisor(s)
Abstract(s)
In non-valvular-associated atrial fibrillation (AF), direct oral anticoagulants
(DOAC) are as effective as vitamin K antagonists (VKA) for the prevention of acute ischemic stroke
(AIS). DOAC are associated with decreased risk and severity of intracranial hemorrhage. It is
unknown if different pre-admission anticoagulants impact the prognosis of AF related AIS (AF-AIS).
We sought to analyze the literature to assess the association between pre-admission anticoagulation
(VKA or DOAC) and admission severity of AF-AIS. Methods: A Systematic literature search (PubMed
and ScienceDirect) between January 2011 to April 2021 was undertaken to identify studies describing
the outcome of AF-AIS. Results: A total of 128 articles were identified. Of 9493 patients, 1767 were
on DOAC, 919 were on therapeutical VKA, 792 were on non-therapeutical VKA and 6015 were not
anticoagulated. In comparison to patients without anticoagulation, patients with therapeutical VKA
and under DOAC presented with less severe stroke (MD −1.69; 95% CI [−2.71, −0.66], p = 0.001
and MD −2.96; 95% Cl [−3.75, −2.18], p < 0.00001, respectively). Patients with non-therapeutical
VKA presented with more severe stroke (MD 1.28; 95% Cl [0.45, 2.12], p = 0.003). Conclusions: In
AF-AIS, patients under therapeutical VKA or DOAC have reduced stroke severity on admission in
comparison to patients without any anticoagulation, with higher magnitude of protection for DOAC.
Description
Keywords
Ischemic stroke Atrial fibrillation Oral anticoagulation Stroke severity
Citation
Journal of Clinical Medicine 11 (12): 3563 (2022)
Publisher
MDPI